Clinically relevant survivin inhibitors tested on various GBM cell lineages, along with their respective molecular structure, half-maximal inhibitory concentration (IC50), and pathophysiologic effects on glioblastoma tissues. The gene discussed is BIRC5; the disease is glioblastoma.